AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06691802
Drug: Shu Fei Tie placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
Trial: NCT06141460
Drug: RRG001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via Subretinal injection. Dosage form: injection solution.
Trial: NCT06192186
Drug: Placebo combined with SOX (S-1/oxaliplatin) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
Trial: NCT06694298
Drug: SYS6020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion
Trial: NCT06695962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 per day for 21 days
Trial: NCT06689124
Drug: Nebulized fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
Trial: NCT06690177
Drug: EscharEx (EX-03)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
Trial: NCT06690177
Drug: Placebo (Gel vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Trial: NCT06687993
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral intake for 90 days
Trial: NCT06694597
Drug: Astragalus Membranaceus Root
RxNorm normalized name: ASTRAGALUS MEMBRANACEUS ROOT POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus tablets 15g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
Trial: NCT06691061
Drug: JAK Inhibitor
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC patients treated with JAK inhibitors
Trial: NCT06689150
Drug: Drospinetta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the three different types of POPs, the new POPs Drosperinon 4 mg, Desogestrel 75 pg, and Levonorgestrel 30 pg in healthy female subjects as regard to the contraceptive efficacy, bleeding pattern, acceptability and safety
Trial: NCT06306157
Drug: Placebo sugar capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
Trial: NCT06067893
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives normal saline for 48 hours post-operatively
Trial: NCT04985110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
Trial: NCT04898309
Drug: GNR-038, 50 МЕ/ kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
Trial: NCT04898309
Drug: GNR-038, 100 МЕ/ kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
Trial: NCT04898309
Drug: Berinert®, 20 МЕ/ kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
Trial: NCT04898309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
Trial: NCT04898309
Drug: GNR-038. The dose will be selected according to results of stage 1 clinical trial.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
Trial: NCT06548672
Drug: BC3195
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
Trial: NCT04989166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06057103
Drug: ZX-7101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral
Trial: NCT05539911
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mic fentanyl added as an adjuvant
Trial: NCT06569784
Drug: [14C]HSK31858
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
Trial: NCT06164600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
Trial: NCT05948943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Stage 2, participants will receive matching placebo for 24 weeks of the study
Trial: NCT04994483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given b.i.d. for 52 weeks.
Trial: NCT06404086
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Trial: NCT06404086
Drug: Melantonin Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Trial: NCT05445804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Chain Triglyceride oil
Trial: NCT05857878
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05773586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06643962
Drug: Idarubincin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
Trial: NCT05997615
Drug: AMX-500 (SAR446329)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
Trial: NCT05658640
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT04943068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
Trial: NCT06574360
Drug: S1RA plus Placebo Cap
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of an S1R agonist plus placebo as a comparator
Trial: NCT06674759
Drug: Tongren-Dahuoluo Bolus Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.72g,2 times a day, oral, for 12 weeks.
Trial: NCT06546735
Drug: Vesomni®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
Trial: NCT06684379
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of saline solution 0.9% for infusion
Trial: NCT06684379
Drug: PRS CK STORM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PRS CK STORM (dose A) for infusion
Trial: NCT06684379
Drug: PRS CK STORM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PRS CK STORM (dose B) for infusion.
Trial: NCT05781750
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of placebo
Trial: NCT06539260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
Trial: NCT06284798
Drug: NNC0650-0013 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0650-0013 will be administered subcutaneously or intravenously.
Trial: NCT06284798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration.
Trial: NCT05702489
Drug: ZX-7101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a drug to treatment influenza in Chinese adults
Trial: NCT04914273
Drug: Inhalation Spray
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg salbutamol administered per metered dose inhaler
Trial: NCT04914273
Drug: Tablet
RxNorm normalized name: TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg salbutamol administered per tablet for ingestion
Trial: NCT05665751
Drug: TLC-3595 Dose 1
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05665751
Drug: TLC-3595 Dose 2
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05665751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05035927
Drug: TRYP-0082
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
Trial: NCT06638086
Drug: Acetaminophen Suppositories
RxNorm normalized name: Acetaminophen Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per rectal suppositories
Trial: NCT06638086
Drug: Acetaminophen Injection
RxNorm normalized name: acetaminophen Injection
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-venous injection
Trial: NCT03817515
Drug: ABI-009
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus Albumin-bound Nanoparticles
Trial: NCT06319274
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously infusion for 72 hours at 3 ml/hours
Trial: NCT05181085
Drug: NST 6179
RxNorm normalized name: GLOVE NITRILE SM PFREE NSTERL TX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
Trial: NCT05181085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive analogue
Trial: NCT04818086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.
Trial: NCT05656274
Drug: JS1-1-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tables
Trial: NCT05656274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tables
Trial: NCT05269940
Drug: ZX-101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dosing, once daily
Trial: NCT06015165
Drug: Analgesia plan for Anes. Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.
Trial: NCT06015165
Drug: Analgesia plan for Surg. Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.
Trial: NCT06643247
Drug: Drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
Trial: NCT06525870
Drug: 85%TCA topical application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
Trial: NCT06525870
Drug: 3% acetic acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
Trial: NCT06500871
Drug: Diclofenac Potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NSAID
Trial: NCT05782244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, TID
Trial: NCT06530303
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Trial: NCT04636437
Drug: Integrase strand transfer inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Trial: NCT05936138
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04791020
Drug: Lidocain topical + paracervical blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
Trial: NCT05156814
Drug: Femoston® 1, Femoston® 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
Trial: NCT05156814
Drug: Klimadynon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifuga racemosa rhizomatum extract
Trial: NCT04831619
Drug: PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
Trial: NCT06480461
Drug: VGN-R09b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
Trial: NCT05262764
Drug: JARDIANCE®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JARDIANCE®
Trial: NCT05003336
Drug: Xiangshao Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
Trial: NCT05003336
Drug: Xiangshao Granules Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiangshao Granules Placebo
Trial: NCT06011889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
Trial: NCT06670521
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline placebo IV every 6 hours for 4 doses
Trial: NCT06297213
Drug: R-2487
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-2487 DP
Trial: NCT06671665
Drug: calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
Trial: NCT06671054
Drug: AP1189, 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1189 tablets for oral use
Trial: NCT06671054
Drug: AP1189, 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1189 tablets for oral use
Trial: NCT06671054
Drug: AP1189, 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1189 tablets for oral use
Trial: NCT06671054
Drug: AP1189 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1189 tablets for oral use
Trial: NCT06613139
Drug: YHP2305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: YHP2305 Comparator: YHR2404
Trial: NCT06613139
Drug: YHR2404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: YHP2305 comparator: YHR2404
Trial: NCT06676085
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: unfractionated heparin for anticoagulation
Trial: NCT05865886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1291583
Trial: NCT06675214
Drug: Full course of PD-1/PD-L1 blockades
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Trial: NCT06689852
Drug: Loceryl 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be used once a week
Trial: NCT06689254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05405166
Drug: Paracetamol / Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
Trial: NCT05298046
Drug: Experimental: TAVO101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAVO101 single ascending dose IV infusion.
Trial: NCT04921306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
Trial: NCT05755685
Drug: Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
Trial: NCT04956900
Drug: Aurase Wound gel
RxNorm normalized name: hyaluronate Topical Gel [IPM Wound]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.
Trial: NCT05018598
Drug: Administration via pressurized metered dose inhaler (pMDI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5993 pMDI
Trial: NCT05018598
Drug: Administration via pressurized metered dose inhaler (pMDI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 pMDI or CHF5993 pMDI
Trial: NCT06642844
Drug: Avastin, 25 Mg/mL Intravenous Solution
RxNorm normalized name: Avastin, 25 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.